ReviewClinical immunology (Orlando, Fla.)2020
Psoriatic arthritis under the influence of IFNγ.
Review in Clinical immunology (Orlando, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Trial
- Apremilast therapy increases CD39Rheumatology international · 2026Observational
- IL-23 and monocyte interactions redirect human Th17.1 cells to an IL-17AFrontiers in immunology · 2026Article
- Tyrosine kinase 2 inhibitors in the therapy of inflammatory and autoimmune diseases.Pharmacological reports : PR · 2025Review
- IFN-γ and IL-22 in premature ovarian insufficiency correlation with ovarian reserve markers and pathogenic implications: a cross-sectional study.BMC women's health · 2025Article
- Article
- Comprehensive Profiling of Cytokines and Growth Factors: Pathogenic Roles and Clinical Applications in Autoimmune Diseases.International journal of molecular sciences · 2025Review
- An Immunomodulating Peptide with Potential to Promote Anticancer Immunity Without Compromising Immune Tolerance.Biomedicines · 2025Article
- Interleukin-6 in synovial fluid drives the conversion of DC2s to DC3s in inflammatory arthritis.iScience · 2025Article
- Novel association of chilblains with inflammatory arthritis- series of three cases and review of literature.Rheumatology international · 2025Review
- Interventions in cytokine signaling: novel horizons for psoriasis treatment.Frontiers in immunology · 2025Review
- Article
- Natural Product-Derived Compounds Targeting Keratinocytes and Molecular Pathways in Psoriasis Therapeutics.International journal of molecular sciences · 2024Review
- DNA methylation patterns in CD4Frontiers in immunology · 2023Article
- A role for whey acidic protein four-disulfide-core 12 (WFDC12) in the pathogenesis and development of psoriasis disease.Frontiers in immunology · 2022Article
- Translational Research Studies Unraveling the Origins of Psoriatic Arthritis: Moving Beyond Skin and Joints.Frontiers in medicine · 2021Article
- Psoriatic arthritis; overcoming the challenges by creating opportunities.Clinical immunology (Orlando, Fla.) · 2020Article
- Innate Lymphocytes in Inflammatory Arthritis.Frontiers in immunology · 2020Review
- Biomarkers in Psoriasis: The Future of Personalised Treatment.Indian journal of dermatologyArticle
- The Role of TNF - α, IFN - γ, and IL-6 in Guiding Treatment and Predicting Prognosis in the Treatment of Severe Plaque Psoriasis with Adalimumab.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Psoriasis is a common multifactorial autoimmune disease of the skin, and in a large percentage of patients, immune responses involve nail and joint pathology, which develop psoriatic arthritis (PsA). Historically, T helper 1 (Th1)-derived-IFN-γ was abundantly detected in psoriatic skin and its correlation with development and severity of PsO, led to an early classification of psoriasis as a Th1-mediated disease. Investigations of the cellular and molecular mechanisms of PsO pathogenesis in recent years, together with impressive results of biologics against interleukin 17A (IL-17) have shifted focus on IL-17A. However, the contributions of IFN-γ in IL-17 induced pathology and its involvement in the development of PsA have been largely overshadowed. This review summarizes the current knowledge on IFN-γ and provides new insights on the contribution of IFN-γ to PsO and PsA disease pathogenesis and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.